About: Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.39 (-5.89%)
MBIO NASDAQ Mustang Bio Inc
Mustang Bio Inc share price
MBIO price activity
Last Price
$0.390
Change (24hr)
-0.02 USD (-5.89%)
Volume
8.15K
Volume (4w avg)
-
Open
$0.39
Day Range
$0.39 - $0.40
Previous Close
$0.41
Last Trade
13 Oct, 7:06 pm GMT+0
Delayed
13 Oct, 7:06 pm GMT+0
MBIO price performance
Delayed
13 Oct, 7:06 pm GMT+0
MBIO Market Signals